Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 9;388(10):950-952.
doi: 10.1056/NEJMc2216309. Epub 2023 Feb 15.

Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis

Luca Huth  1 , Luise Schäfer  1 , Giovanni Almanzar  1 , Gaia Lupoli  2 , Marie Bischof  2 , Paul R Wratil  2 , Torsten Stövesand  3 , Christiane Drechsler  3 , Oliver T Keppler  2 , Martina Prelog  4
Affiliations

Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis

Luca Huth et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Anti-Spike IgG Responses against Omicron BA.4 and BA.5 Subvariants before and after Bivalent mRNA Booster in Patients Undergoing Hemodialysis.
Anti-spike IgG concentrations 6 and 2 weeks before, as well as 2 and 4 weeks after, fifth messenger RNA (mRNA) vaccination in patients with previous B.1.1.529 (omicron) breakthrough infection (open circles) and those with no previous omicron breakthrough infection (triangles) are shown (Panel A). Connecting lines between the time points indicate matched serum samples. The dashed horizontal line indicates the lower limit of detection (31 binding antibody units [BAU] per milliliter) in the detection system. Neutralizing activities are presented as serum dilutions for half-maximal infection-neutralization capacities normalized to 107 viral RNA copies (50% inhibitory concentration [IC50]) for omicron BA.4 (Panel B) and BA.5 (Panel C). The anti-spike IgG antibody avidities are shown as relative percentages for three time points (Panel D). The median value (horizontal line) and interquartile range (whiskers) are shown. P values are given for comparison of the dependent variables between different time points for each group. For comparison between patients with previous omicron breakthrough infection and those with no previous omicron breakthrough infection at each time point, one asterisk denotes P<0.05, two asterisks P<0.01, and three asterisks P<0.001.
See this image and copyright information in PMC

References

    1. Anft M, Blazquez-Navarro A, Frahnert M, et al. Inferior cellular and humoral immunity against omicron and delta variants of concern compared with SARS-CoV-2 wild type in hemodialysis patients immunized with 4 SARS-CoV-2 vaccine doses. Kidney Int 2022;102:207-208. - PMC - PubMed
    1. Carr EJ, Wu M, Harvey R, et al. Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients. Lancet 2022;399:800-802. - PMC - PubMed
    1. Wratil PR, Stern M, Priller A, et al. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nat Med 2022;28:496-503. - PubMed
    1. Keppler-Hafkemeyer A, Greil C, Wratil PR, et al. Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma. Nat Cancer 2023;4:81-95. - PMC - PubMed
    1. Chalkias S, Harper C, Vrbicky K, et al. A bivalent omicron-containing booster vaccine against Covid-19. N Engl J Med 2022;387:1279-1291. - PMC - PubMed

Publication types

MeSH terms